Study Links 70 BRCA2 Variants to Breast Cancer Risk
Mayo Clinic researchers found moderate breast cancer risk tied to specific partial-disruption variants in the BRCA2 gene.
Updated on Nov. 17, 2026 in Cancer

Live Poll
Would you trust your doctor to tailor your breast cancer screening to your specific gene risk?
Mayo Clinic researchers identified 70 variants of the BRCA2 gene that partially disrupt its function and carry a moderate risk of breast cancer. The findings were published in Nature Communications.
Why it matters
Carriers of these variants have an estimated 20% to 25% lifetime risk of breast cancer, a level well below the 50% to 70% risk tied to more common harmful BRCA2 variants. Understanding these differences could help match prevention and screening strategies to individual risk across the United States.
The study examined 70 BRCA2 variants that partially disrupt gene function, with carriers showing an estimated 20% to 25% lifetime breast cancer risk versus 50% to 70% for more common harmful BRCA2 variants. The full set of hypomorphic variants has not yet been identified.
The players
Mayo Clinic
Mayo Clinic is a nonprofit academic medical center based in Rochester, Minnesota, known for its research and clinical care across many specialties.
Ambry Genetics
Ambry Genetics is a genetic testing company that collaborates with researchers on hereditary cancer risk studies.
The details
The research team, working in collaboration with investigators from Ambry Genetics, found that these variants cause a partial loss of BRCA2 function. Some tumors linked to the variants may respond to PARP inhibitors, drugs that block cancer cells from repairing damaged DNA.
Timeline
The study findings were published on November 17, 2026.
Health Landscape
The findings extend decades of BRCA2 research by separating partially disruptive variants from the more common harmful variants long associated with high lifetime breast cancer risk. This refinement could reshape how clinicians stratify hereditary cancer risk in the United States.
Individuals with a family history of breast cancer may eventually receive risk assessments that account for whether they carry partial-disruption BRCA2 variants. Discussing genetic testing and screening options with a clinician can help determine which strategies fit personal risk.
The takeaway
Not every harmful gene variant carries the same risk, and newer research is helping separate higher-risk from moderate-risk carriers. Readers with a family history of breast cancer can ask their doctor whether genetic counseling fits their situation.
Further reading
Explore more on Cancer research and risk factors in the United States.
Source note: This article includes information reported by KIMT-TV 3 Mason City.
Live Poll
Would you trust your doctor to tailor your breast cancer screening to your specific gene risk?










